Collins Laura C, Achacoso Ninah, Nekhlyudov Larissa, Fletcher Suzanne W, Haque Reina, Quesenberry Charles P, Puligandla Balaram, Alshak Najeeb S, Goldstein Lynn C, Gown Allen M, Schnitt Stuart J, Habel Laurel A
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue Boston, MA 02215, USA.
Am J Surg Pathol. 2009 Dec;33(12):1802-8. doi: 10.1097/pas.0b013e3181b7cb7a.
Prior studies have shown that young patient age at diagnosis is associated with an increased risk of local recurrence among women with ductal carcinoma in situ (DCIS) treated with breast-conserving therapy. Whether this can be explained by differences in clinical or pathologic features of DCIS according to age is an unresolved issue. We compared clinical and pathologic features of DCIS among 657 women in 4 age groups: <45 years (n=111), 45 to 54 years (n=191), 55 to 64 years (n=160), and 65+ years (n=195). DCIS presented as a mammographic abnormality less often in younger than in older women (68%, 82%, 81%, and 86% for women <45, 45 to 54, 55 to 64, and 65+ y, respectively; P=0.003). Among the pathologic features analyzed, DCIS extent as determined by the number of low power fields was greater in younger than in older women (mean number of low power fields were 18.6, 14.2, 10.8, and 11.3 in women <45, 45 to 54, 55 to 64 and 65+ y; P<0.001). In addition, cancerization of lobules was present more often in younger than in older women (77%, 73%, 66%, and 50% for women <45, 45 to 54, 55 to 64 and 65+ y, respectively; P<0.0001). Of note, we found no statistically significant relationship between age and DCIS architectural pattern, nuclear grade, comedo necrosis or expression of estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2. We conclude that DCIS in younger women is more often symptomatic, is more extensive, and more often shows cancerization of lobules than DCIS in older women. Whether these features contribute to the higher local recurrence risk in young women with DCIS treated with the breast-conserving therapy requires further study.
既往研究表明,在接受保乳治疗的导管原位癌(DCIS)女性患者中,诊断时年龄较轻与局部复发风险增加相关。DCIS的临床或病理特征是否因年龄而异,这一问题尚未得到解决。我们比较了657名4个年龄组女性的DCIS临床和病理特征:<45岁(n = 111)、45至54岁(n = 191)、55至64岁(n = 160)和65岁及以上(n = 195)。与老年女性相比,DCIS在年轻女性中表现为乳腺钼靶异常的情况较少(<45岁、45至54岁、55至64岁和65岁及以上女性的比例分别为68%、82%、81%和86%;P = 0.003)。在所分析的病理特征中,根据低倍视野数量确定的DCIS范围在年轻女性中比老年女性更大(<45岁、45至54岁、55至64岁和65岁及以上女性的低倍视野平均数量分别为18.6、14.2、10.8和11.3;P<0.001)。此外,小叶癌变在年轻女性中比老年女性更常见(<45岁、45至54岁、55至64岁和65岁及以上女性的比例分别为77%、73%、66%和50%;P<0.0001)。值得注意的是,我们发现年龄与DCIS的结构模式、核分级、粉刺样坏死或雌激素受体、孕激素受体或人表皮生长因子受体2的表达之间无统计学显著关系。我们得出结论,与老年女性的DCIS相比,年轻女性的DCIS更常出现症状,范围更广,且更常表现为小叶癌变。这些特征是否导致接受保乳治疗的年轻DCIS女性局部复发风险更高,需要进一步研究。